Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March ...

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Switzerland ,London ,City Of ,United Kingdom ,Matt Gline ,Melissa Epperly ,Pat Machado ,Anchorage Capital Group ,Morgan Stanley ,Bain Company ,Roivant Sciences Forward ,Zentalis Pharmaceuticals Inc ,Boehringer Ingelheim ,Goldman Sachs ,Nasdaq ,Pfizer ,Development Expenses ,Roivant Sciences ,Sumitomo Pharma Co Ltd ,University Of Virginia ,Roivant Sciences Ltd ,Psioxus Therapeutics Ltd ,Exchange Commission ,Harvard Business School ,Kinnate Biopharma Inc ,Securities Exchange ,Head Of Business Development ,Blueprint Medicines ,Chief Executive Officer ,Chief Financial Officer ,Zentalis Pharmaceuticals ,Business Development ,Vice President ,Kinnate Biopharma ,Harvard Business ,Fiscal Year Ended March ,In Process Research ,Silicon Therapeutics ,Oncopia Therapeutics ,Months Ended March ,Ended March ,Adverse Events ,Securities Act ,Securities Exchange Act ,Risk Factors ,Investors Roivant Investor Relations ,Media Paul Davis Roivant , ,